Drug Profile
LHC 165
Alternative Names: LHC-165Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Novartis
- Class Amines; Antineoplastics; Naphthyridines; Organophosphorus compounds; Propionic acids; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Germany (Intratumoural, Injection)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in South Korea (Intratumoural, Injection)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain (Intratumoural, Injection)